CN1240717C - 低毒性的人干扰素－α类似物 - Google Patents

低毒性的人干扰素－α类似物 Download PDF

Info

Publication number
CN1240717C
CN1240717C CNB988103680A CN98810368A CN1240717C CN 1240717 C CN1240717 C CN 1240717C CN B988103680 A CNB988103680 A CN B988103680A CN 98810368 A CN98810368 A CN 98810368A CN 1240717 C CN1240717 C CN 1240717C
Authority
CN
China
Prior art keywords
leu
ifn
amino acid
analog
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988103680A
Other languages
English (en)
Chinese (zh)
Other versions
CN1276797A (zh
Inventor
霍华德·M·约翰逊
卡罗尔·H·庞特泽
洛勒莱·H·维拉雷特
雅克利纳·坎波斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Pepgen Corp
Original Assignee
University of Florida
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, Pepgen Corp filed Critical University of Florida
Publication of CN1276797A publication Critical patent/CN1276797A/zh
Application granted granted Critical
Publication of CN1240717C publication Critical patent/CN1240717C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB988103680A 1997-10-20 1998-10-20 低毒性的人干扰素－α类似物 Expired - Fee Related CN1240717C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs
US08/954,395 1997-10-20

Publications (2)

Publication Number Publication Date
CN1276797A CN1276797A (zh) 2000-12-13
CN1240717C true CN1240717C (zh) 2006-02-08

Family

ID=25495373

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988103680A Expired - Fee Related CN1240717C (zh) 1997-10-20 1998-10-20 低毒性的人干扰素－α类似物

Country Status (13)

Country Link
US (1) US6204022B1 (https=)
EP (1) EP1025124B1 (https=)
JP (2) JP2001520238A (https=)
KR (2) KR100586625B1 (https=)
CN (1) CN1240717C (https=)
AT (1) ATE402957T1 (https=)
AU (1) AU744774B2 (https=)
CA (1) CA2308116C (https=)
DE (1) DE69839812D1 (https=)
DK (1) DK1025124T3 (https=)
ES (1) ES2310931T3 (https=)
TW (1) TW593336B (https=)
WO (1) WO1999020653A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
AU781377B2 (en) * 1999-08-27 2005-05-19 University Of Florida Research Foundation, Inc. Materials and methods for inhibition of IgE production
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
KR20040022244A (ko) 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
RU2288474C1 (ru) * 2005-12-28 2006-11-27 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) Способ определения токсического действия оральной мукозальной интерферонотерапии
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (en) 1986-03-31 1989-02-01 Interferon Sciences, Inc. An alpha interferon analogue
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Also Published As

Publication number Publication date
DE69839812D1 (de) 2008-09-11
CA2308116A1 (en) 1999-04-29
EP1025124B1 (en) 2008-07-30
EP1025124A1 (en) 2000-08-09
JP2008247926A (ja) 2008-10-16
AU744774B2 (en) 2002-03-07
US6204022B1 (en) 2001-03-20
KR20060015701A (ko) 2006-02-17
ATE402957T1 (de) 2008-08-15
WO1999020653A1 (en) 1999-04-29
CN1276797A (zh) 2000-12-13
DK1025124T3 (da) 2008-10-06
KR100861007B1 (ko) 2008-09-30
TW593336B (en) 2004-06-21
KR20010031206A (ko) 2001-04-16
ES2310931T3 (es) 2009-01-16
KR100586625B1 (ko) 2006-06-07
JP2001520238A (ja) 2001-10-30
CA2308116C (en) 2010-12-14
AU9807298A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
CN1240717C (zh) 低毒性的人干扰素－α类似物
CN1219796C (zh) 干扰素－τ多肽的N－末端氨基酸序列的应用
CN1241638C (zh) Ifnar2/ifn复合物
CN1090510A (zh) 干扰素-τ组成物及其用途
CN1224707C (zh) 白细胞介素－1受体拮抗剂的细胞内同种型
CN1309423C (zh) 干扰素γ偶联物
CN1509337A (zh) IFNα-17基因的新的多核苷酸和多肽
CN1568369A (zh) 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法
CN1531600A (zh) IFNα-21基因的新的多核苷酸和多肽
CN1257186C (zh) 干扰素γ多肽变体
CN1285381C (zh) 多发性硬化症治疗中所用的趋化因子突变体
CN101062952A (zh) 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用
CN1161468C (zh) Mpl配体类似物
CN1269840C (zh) 长效的人干扰素类似物
CN1082112A (zh) 脂肪生成抑制因子的衍生物、其制备方法及其用途
CN1187447C (zh) Mpl配体类似物
CN1313491C (zh) 猫ω干扰素及其编码基因与应用
CN1112127A (zh) 新的蛋白质p140多肽及编码该多肽的DNA
CN1220702C (zh) 促胰岛素分泌肽及其用途
CN1896104A (zh) 细胞抑制因子与白蛋白的融合蛋白
CN1186448C (zh) 重组人α胸腺素原－白介素2基因及其表达、应用
CN1740197A (zh) 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
CN1746306A (zh) 一种重组人干扰素α4编码cDNA序列及其制备方法和应用
CN1532284A (zh) 一种新型抗菌多肽及其制备方法
CN1198842C (zh) 具有细胞趋化作用和造血刺激活性的趋化素样因子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060208

Termination date: 20111020